Médicaments innovants et prix conditionnels: le contrat de performance, à l'opposé du partage de risques = Conditional pricing for innovative medicines in France: Stop telling about risk-sharing!MEGERLIN, F.Annales pharmaceutiques françaises. 2013, Vol 71, Num 5, pp 291-301, issn 0003-4509, 11 p.Article

L'évaluation médico-économique des produits de santé dans le contexte de la loi de financement de la Sécurité sociale pour 2012DERVAUX, Benoît; BASEILHAC, Eric; DETOURNAY, Bruno et al.Thérapie (Paris). 2013, Vol 68, Num 4, pp 253-257, issn 0040-5957, 5 p.Conference Paper

MARKETING: Les leaders d'opinion, instrument marketing des firmesLa Revue Prescrire. 2012, Vol 32, Num 341, pp 219-221, issn 0247-7750, 3 p.Article

eCTD: soumission électronique des dossiers d'AMM = eCTD: electronic submission of MA dossiersROUVET, E; COURTOT-LACROIX, C; SCHILDER, S et al.STP pharma pratiques. 2011, Vol 21, Num 6, pp 439-458, issn 1157-1497, 20 p.Article

An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessibleVIERECK, Christopher; BOUDES, Pol.Contemporary clinical trials. 2009, Vol 30, Num 4, pp 293-299, issn 1551-7144, 7 p.Article

Mondialisation : Contrefaçons de médicaments : vrais et faux problèmes = Globalization : drugs counterfeit : truths and non-problemLa Revue Prescrire. 2009, Vol 29, Num 306, pp 298-303, issn 0247-7750, 6 p.Article

Point de vue d'un sous-traitant sur le système partagé = Contract manufacturing organisation point of view on the global systemLAUNAY-DUPRIEZ, M.-A.STP pharma pratiques. 2009, Vol 19, Num 6, pp 475-480, issn 1157-1497, 6 p.Conference Paper

Recent National and Regional Drug Reforms in Sweden : Implications for Pharmaceutical Companies in EuropeWETTERMARK, Björn; GODMAN, Brian; ANDERSSON, Karolina et al.PharmacoEconomics (Auckland). 2008, Vol 26, Num 7, pp 537-550, issn 1170-7690, 14 p.Article

Scientific advice and protocol assistance by the EMEA : Recent developmentsVAN TROOSTENBURG, Anne-Ruth; TABUSSO, Giuliana; BOSONE, Enrico et al.International journal of pharmaceutical medicine. 2006, Vol 20, Num 4, pp 227-231, issn 1364-9027, 5 p.Article

The role of pharmacists in the evolution of health care : An open forum discussionKELLY, H. William.Pharmacotherapy. 2006, Vol 26, Num 9, issn 0277-0008, 200S-202S, 2Conference Paper

Managing drug shortages: Seven years' experience at one health systemFOX, Erin R; TYLER, Linda S.American journal of health-system pharmacy. 2003, Vol 60, Num 3, pp 245-253, issn 1079-2082, 9 p.Article

Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?ABRAHAM, John; REED, Tim.Social science & medicine (1982). 2003, Vol 57, Num 2, pp 195-204, issn 0277-9536, 10 p.Article

Autorisation temporaire d'utilisation. Comment s'exerce la pharmacovigilance = Temporary authorization for use. How to apply postmarketing surveillance?DEMAREZ, J. P; BOUDIGNAT, O; LAMARQUE, V et al.La Lettre du pharmacologue (Boulogne). 2002, Vol 16, Num 1, pp 16-21, issn 0984-452XArticle

Design, analysis and presentation of multinational economic studies: The need for guidancePANG, Francis.PharmacoEconomics (Auckland). 2002, Vol 20, Num 2, pp 75-90, issn 1170-7690Article

Physicians' interpretation of class effects: A need for thoughtful re-evaluationKENNEDY, Harold L; ROSENSON, Robert S.Journal of the American College of Cardiology. 2002, Vol 40, Num 1, pp 19-26, issn 0735-1097Article

Promotion of prescription drugs to consumersROSENTHAL, Meredith B; BERNDT, Ernst R; DONOHUE, Julie M et al.The New England journal of medicine. 2002, Vol 346, Num 7, pp 498-505, issn 0028-4793Article

La pharmacologie de sécurité : une réalité réglementaire. Implications = Regulatory status of safety pharmacology: the implicationsBARBIER, A; CAILLE, D.Thérapie (Paris). 2002, Vol 57, Num 2, pp 104-108, issn 0040-5957Conference Paper

War and peace in the new yearWILLIAMS, David.Medical device technology. 2001, Vol 12, Num 10, pp 7-9, issn 1048-6690Article

Do we need research incentives for health claims?CHILDS, Nancy M; CHILDS, Michael E.Chemical innovation. 2001, Vol 31, Num 8, pp 28-37, issn 1527-4799Article

Médicaments: exiger les informations des agences publiques = Drugs: Require the informations of public agenciesLa Revue Prescrire. 2001, Vol 21, Num 217, pp 381-382, issn 0247-7750Article

The relationship between European paediatricians and commerce: Ethical principles in paediatrics working group recommendations. Confederation of European Societies of Paediatrics (CESP)CHAMBERS, T. L.European journal of pediatrics. 2000, Vol 159, Num 1-2, pp 116-118, issn 0340-6199Article

L'emploi dans l'industrie pharmaceutique. Un marché porteur malgré les fusionsRAJNCHAPEL-MESSAI, Jocelyne.PHARMACEUTIQUES : SANTE, MEDICAMENT ET INDUSTRIE. 2000, Num 77, pp 59-65, 4 p.Article

The development of standard economic datasets for use in the economic evaluation of medicinesBACKHOUSE, Martin E; GNANASAKTHY, Ari; SCHULMAN, Kevin A et al.Drug information journal. 2000, Vol 34, Num 4, pp 1273-1291, issn 0092-8615Article

Agence européenne pour l'évaluation des médicaments : Bilan de cinq ans d'expérience = European agency for drugs evaluation :Five years experience resultsSAUER, F.Bulletin et mémoires de l'Académie Royale de Médecine de Belgique. 2000, Vol 155, Num 5-6, pp 254-258, issn 0377-8231Article

La distribution pharmaceutique américaineSIMONET, D.Journal d'économie médicale. 2000, Vol 18, Num 3-4, pp 233-240, issn 0294-0736Article